Microlight3D, a French company specializing in high-resolution, micro-scale 3D printing technologies, has received a European grant worth €747,000 ($822,000) for the nAngioDerm project in which it is a partner. A consortium of research groups from across Europe will distribute the funding, including ANR (the French National Research Agency), which is underwriting Microlight3D’s work in the project.
The nAngioDerm project will officially launch in September 2019 and is scheduled to run for the next 36 months. Broadly, its goal is to develop a 3D printing process for dermal regeneration. Microlight 3D and four other European research partners will collaborate to develop a novel solution for patients who are suffering from hard-to-heal wounds caused by ulcers or burns.
Over the next three years, Microlight3D and its partners will pioneer a new 3D printing process and associated products using ion-release biomaterials designed to promote angiogenesis for dermal regeneration. To achieve this, the project will rely heavily on the partners’ respective expertise in tissue engineering, bio-active ions and cell-scaffold 3D printing—Microlight3D’s speciality.
“Microlight3D is very proud to be a partner in nAngioDerm, its first European research consortium,” commented Denis Barbier, CEO of Microlight3D. “Collaborating with such high-level academic organizations on such a key health issue is further recognition of the value of our 3D microprinting technology for regenerative medicine applications. This project is a great opportunity in helping to further develop our micro-scale 3D printing systems for use in future health applications.”
The nAngioDerm project is being led by the Institute for Bioengineering in Catalonia (IBEC), which specializes in bio-active ions and bioengineering, and brings on participation from researchers at the University of Ioannina in Greece, the Universitario Vall d’Hebron Hospital in Spain and the University of Grenoble in France.
Microlight3D, the only non-academic partner, will be tasked with developing a 3D printer and process for cell-scaffold applications. The role is critical in the nAngioDerm project and Microlight3D was selected for the job because of its experience and expertise in 3D printing biomaterials with sub-cell resolution.
Down the line, the ability to 3D print biostructures for dermal regeneration could lead to more sophisticated treatment methods for patients suffering from acute wounds caused by ulcers, burns or surgery. The treatment could lead to reduced medical costs and resources for wound care—currently, the annual cost of managing wounds by the NHS is estimated to be upwards of £4.5 billion.
The nAngioDerm project is part of EuroNanoMed3 (2016-2021), an initiative which supports multidisciplinary and translational research and innovation projects focused on regenerative medicine, diagnostics and targeted delivery systems. EuroNanoMed3 is part of the larger European Horizon 2020 program.